MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$21,197K
Free Cash flow
-$15,980K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Stock-based compensation
    • Accrued and other liabilities
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net (loss) income
    • Investment in angel pharmaceutic...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-17,959
-13,692
-12,321
-10,157
Depreciation and amortization
34
29
26
28
Accretion related to marketable securities
-185
17
261
459
Stock-based compensation
2,609
2,650
1,574
1,249
Change in fair value of warrant liability
-
-
0
0
Loss from equity method investment
-709
-599
-707
-323
Accounts receivable - related party
-
-
-
-54
Accounts receivable
-37
6
-38
-
Prepaid and other current assets
2,542
1,762
204
-64
Operating lease right-of-use asset
-92
-88
-88
-85
Other assets
-7
865
3
226
Accounts payable
-650
2,206
517
-1,163
Accrued and other liabilities
2,186
499
765
708
Operating lease liability
-106
-103
-74
-72
Net cash used in operating activities
-15,398
-10,374
-9,191
-9,566
Purchases of marketable securities
47,740
161,737
13,418
31,149
Maturities of marketable securities
47,357
16,982
24,323
28,531
Purchases of property and equipment
582
91
25
0
Investment in angel pharmaceuticals
5,000
-
-
-
Net cash used in investing activities
-5,965
-144,846
10,880
-2,618
Proceeds from the exercise of common stock warrants (includes 4,960 in aggregate gross proceeds from related parties for the year ended december 31, 2025)
-
-
0
0
Proceeds from issuance of common stock in connection with follow-on public offering, net
0
189,407
-
-
Proceeds from exercise of common stock options
166
1,339
20
360
Net cash provided by financing activities
166
190,746
20
360
Net increase in cash and cash equivalents
-21,197
35,526
1,709
-11,824
Cash and cash equivalents at beginning of the period
40,102
4,576
2,867
8,740
Cash and cash equivalents at end of the period
18,905
40,102
4,576
2,867
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from exercise ofcommon stock options$166K (-45.39%↓ Y/Y)Net cash provided byfinancing activities$166K (-99.54%↓ Y/Y)Net increase in cashand cash...-$21,197K (-456.19%↓ Y/Y)Canceled cashflow$166K Stock-based compensation$2,609K (4.07%↑ Y/Y)Accrued and otherliabilities$2,186K (69.72%↑ Y/Y)Loss from equitymethod investment-$709K (23.60%↑ Y/Y)Accretion related tomarketable securities-$185K (-129.60%↓ Y/Y)Operating leaseright-of-use asset-$92K (44.24%↑ Y/Y)Accounts receivable-$37K Depreciation andamortization$34K (-33.33%↓ Y/Y)Other assets-$7K (-16.67%↓ Y/Y)Maturities of marketablesecurities$47,357K (51.43%↑ Y/Y)Net cash used inoperating activities-$15,398K (-9.67%↓ Y/Y)Net cash used ininvesting activities-$5,965K (62.85%↑ Y/Y)Canceled cashflow$5,859K Canceled cashflow$47,357K Net (loss) income-$17,959K (-349.60%↓ Y/Y)Purchases of marketablesecurities$47,740K (1.18%↑ Y/Y)Prepaid and othercurrent assets$2,542K (335.15%↑ Y/Y)Accounts payable-$650K (-217.12%↓ Y/Y)Operating lease liability-$106K (-171.79%↓ Y/Y)Investment in angelpharmaceuticals$5,000K Purchases of property andequipment$582K (290.60%↑ Y/Y)

Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals, Inc. (CRVS)